Ovarian epithelial cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ovarian epithelial cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer https://clinicaltrials.eu/trial/study-of-sacituzumab-tirumotecan-and-bevacizumab-for-patients-with-recurrent-ovarian-cancer/ Wed, 29 Apr 2026 15:04:10 +0000 https://clinicaltrials.eu/trial/study-of-sacituzumab-tirumotecan-and-bevacizumab-for-patients-with-recurrent-ovarian-cancer/ This clinical trial is focused on studying treatments for ovarian cancer, specifically in cases where the cancer has returned after initial treatment. The study will explore the effectiveness and safety of a treatment called sacituzumab tirumotecan, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific substances in the body. In this study, sacituzumab tirumotecan will be used alone or in combination with another medication called bevacizumab, which is also a monoclonal antibody that helps prevent the growth of blood vessels that feed tumors.

The purpose of the study is to evaluate how well these treatments work in maintaining the health of patients with platinum-sensitive recurrent ovarian cancer. This means the cancer has responded to platinum-based chemotherapy in the past but has come back. The study will compare the effects of sacituzumab tirumotecan with or without bevacizumab against the standard care, which may include observation or the use of bevacizumab. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein.

The study will be conducted in two parts. The first part will focus on assessing the safety and how well patients tolerate the treatment. The second part will compare the effectiveness of the treatments in preventing the cancer from getting worse. The study will last for a period of up to 84 days, during which participants will be closely monitored for any side effects and the overall impact on their health. The goal is to find out if these treatments can help improve the quality of life and extend the time patients remain free from cancer progression.

]]> Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location and are difficult to treat. The trial will test a new treatment called DS-3939a, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and tolerability of DS-3939a and to see how well it works in treating these advanced cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

]]>